Search

Submitted by Vitor Silverio Rodrigues (vitorsrodrigues@reitoria.unesp.br) on 2014-05-27T11:24:42Z No. of bitstreams: 0 Made available in DSpace on 2014-05-27T11:24:42Z (GMT). No. of bitstreams: 0 Previous issue date: 2010-06-01 Aim: This study aimed to compare the safety and analgesic efficacy of a new topical drug (in two different presentations: cream and aerosol) consisting of benzocaine, menthol and triclosan, in the curettage of molluscum contagiosum. Method: The study included 296 volunteers in different stages: 256 healthy adult volunteers for the safety evaluation, and 40 volunteers between 2 and 12 years old who presented Molluscum contagiosum, for the evaluation of tolerability and efficacy. Each volunteer represented two experimental units (left and right) where it was applied randomly the tested products (cream or aerosol) 30 minutes before the dermatological curettage, immediately after and twice a day during 7 days. Dermatological evaluations of safety and efficacy were performed immediately after the procedure, 3 and 7 days after the curettage. Results: During safety evaluation, the tested products showed no irritant, sensitizing, phototoxic or photosensitizing potential. Both presentations, cream and aerosol, were considered safe with no statistically significant differences between them. With respect to analgesic efficacy, the results showed that the medication promoted the reduction of painful symptoms and there was no statistically significant difference (p

Submitted by Vitor Silverio Rodrigues (vitorsrodrigues@reitoria.unesp.br) on 2014-05-27T11:24:42Z No. of bitstreams: 0 Made available in DSpace on 2014-05-27T11:24:42Z (GMT). No. of bitstreams: 0 Previous issue date: 2010-06-01 Aim: This study aimed to evaluate the efficacy of a new topical drug (EF028) in two separate presentations (aerosol and cream) in a comparative way with the already registered medication, Andolba® (benzocaine, benzoxiquina chloride benzeconio, menthol) and the negative control (hygiene), in the analgesic efficacy after episiotomy wound, reducing the requirement for systemic medication. Methods: 60 patients were voluntary post normal vaginal childbirth with episiotomy, were divided into four groups to comparatively assess the action of the product EF028 (cream and aerosol), Andolba® and soap, the efficacy of decreasing painful symptoms from daily use for 2 times a day for seven days. Clinical assessments and subjective pain occurred daily until the third postoperative day and on the 7th postoperative day. Results: The results showed that the drugs promoted a reduction of painful symptoms and there was no statistically significant difference (p

O presente estudo aberto teve por objetivo avaliar a eficácia da venlafaxina (inibidor da recaptação da serotonina e da noradrenalina) na prevenção das crises de migrânea com ou sem aura em 42 pacientes com idade média de 32,5 anos e variação de 13 a 48 anos. O sexo feminino predominou sobre o masculino. A avaliação ocorreu de maio a setembro de 1997. O tempo de avaliação foi de 4 meses. A média de crises por mês era 3,8. Os efeitos colaterais mais consistentes foram a perda de peso, náuseas e vômitos. A venlafaxina mostrou-se eficaz em 37 dos 42 pacientes selecionados (88,07 %) com doses variando de 18,75 - 37,5 mg/dia. The present open study intended to show the prophylactic value of venlafaxine (serotonin and noradrenalin reuptake inhibitor) in 42 patients with migraine with or without aura during four months, from May to September 1997. The average age was 32.5 years and average crisis was 3.8 per month. Consistent side-effects included loss of weight, nausea and vomit. The efficacy of drug occurred in 37 patients (88.07%) with dosis of 18.75 to 37.5 mg/day. We conclude that venlafaxine is an effective drug in prophylaxis of migraine patients.